CompletedPhase 1/2Results postedNCT02225366
Intratumoral Injections of LL37 for Melanoma
M.D. Anderson Cancer Center4 participants8 Jul 2015 to 24 Nov 2020
Melanoma
Compare peptides
Compare two to four peptides side by side. Counts are exact.
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Natural fragment LL-37 | Synthetic analog Thymogen (oglufanide) | |
|---|---|---|---|
| Identity | |||
| Kind | Natural fragment | Synthetic analog | |
| Area | Immune and antimicrobial | Immune and antimicrobial | |
| Evidence | |||
| Amount of evidence | 190 (plus 224 on natural levels, listed separately) | 123 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 11 (7 in people) | 4 (3 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 217 more mention it but do not test it | 3 | |
Shared outcomes
From the regulatory data of each peptide.
Its most advanced trial is in phase 2. The FDA, the EMA and the other sources we use show no approval (as of 8 Oct 2026).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | LL-37 | Thymogen (oglufanide) |
|---|---|---|
| Immune responseRespiratory | 19415 | 541125 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
No FDA approval and no central EU authorisation (EMA).
| Inflammation markersSkin and wound | 6121940 | 22 |
|---|
| Infection and antimicrobial activityPharmacology | 381730 | 853 |
|---|
| Wound healingSkin and wound | 16106 | 514 |
|---|
| Adverse eventsWhole body | 9711 | 541 |
|---|
| Receptor activity and mechanismSkin and wound | 19217 | 853 |
|---|
| MortalityWhole body | 99 | 11110 |
|---|
| Antiviral activityInfection | 633 | 22 |
|---|
| Tumor growthCancer | 312 | 99 |
|---|
| Skin and hairSkin and wound | 33 | 11 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
LL-37 is the same as Cathelicidin antimicrobial peptide precursor (hCAP18) residues 134 to 170.
No differences in the aligned region.
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
2 trials · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)
M.D. Anderson Cancer Center4 participants8 Jul 2015 to 24 Nov 2020
Melanoma
Fakultas Kedokteran Universitas Indonesia40 participantsest. Oct 2019 to est. Jan 2020
Diabetic Foot Ulcer
17 more mention it but do not test it. They only measure it or name it in their text.
3 trials · 1 completed · 1 stopped early · source ClinicalTrials.gov (opens in a new tab)
University of Southern California18 participantsNov 1999 to Nov 2001
Colorectal Cancer
CytranStart Jan 2001
Ovarian Cancer · Primary Peritoneal Cavity Cancer
University of Southern California43 participantsFeb 1999 to Aug 2001
Ovarian Cancer